New viral vaccines for dermatologic disease

Journal of the American Academy of Dermatology

Volumn 58, Issue 3, 2008, Pages 361-370

  Urman, Christine Orlova ^a   Gottlieb, Alice B ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; GLYCOPROTEIN E1; IMIQUIMOD; L1 PROTEIN; L2 PROTEIN; PODOPHYLLIN; PROTEIN E6; PROTEIN E7; STRUCTURAL PROTEIN; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VIRUS E2 PROTEIN; VIRUS E4 PROTEIN; VIRUS E5 PROTEIN; VIRUS PROTEIN; WART VIRUS VACCINE;

CANCER MORTALITY; CONDYLOMA ACUMINATUM; CRYOTHERAPY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FEVER; FOOD AND DRUG ADMINISTRATION; HEMATOMA; HERPES ZOSTER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VARICELLA ZOSTER VIRUS; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CONDYLOMATA ACUMINATA; DERMATOLOGY; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 38949113708     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.07.051     Document Type: Review

References (97)

1. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
2. Bosch F.X., and de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31 (2003) 3-13
3. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 (2003) 63-73
4. Clifford G., Franceschi S., Diaz M., Munoz N., and Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24S3 (2006) S326-S334
5. Schiffman M., and Kjaer S.K. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31 (2003) 14-19
6. Favre M., Ramoz N., and Orth G. Human papillomaviruses: general features. Clin Dermatol 15 (1997) 181-198
7. Stoler M.H. The virology of cervical neoplasia: an HPV-associated malignancy. Cancer J 9 (2003) 360-367
8. Palefsky J.M., and Holly E.A. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev 4 (1995) 415-428
9. Evans M.F., Adamson C.S., Papillo J.L., St. John T.L., Leiman G., and Cooper K. Distribution of human papillomavirus types in ThinPrep Papanicolau tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 106 (2006) 1054-1064
10. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., and Pimenta J.M. Human papillomavirus genotype in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1157-1164
11. Lacey C.J., Lowndes C.M., and Shah K.V. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24S3 (2006) S35-S41
12. Brown D.R., Schroeder J.M., Bryan J.T., Stoler M.H., and Fife K.H. Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 37 (1999) 3316-3322
13. Conley L.J., Ellerbrock T.V., Bush T.J., Chiasson M.A., Sawo D., and Wright T.C. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 359 (2002) 108-113
14. Persson G., Dahlof L.G., and Krantz I. Physical and psychological effects of anogenital warts on female patients. Sex Transm Dis 20 (1993) 10-13
15. Wiley D.J., Douglas J., Beutner K., Cox T., Fife K., Moscicki A.B., et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 35 (2002) S210-S224
16. Cates Jr. W. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 26 (1999) S2-S7
17. Bekkers R.L., Massuger L.F., Bulten J., and Melchers W.J. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol 14 (2004) 95-105
18. Grussendorf-Conen E.I., de Villiers E.M., and Gissmann L. Human papillomavirus genomes in penile smears of healthy men. Lancet 2 (1986) 1092
19. Ley C., Bauer H.M., Reingold A., Schiffman M.H., Chambers J.C., Tashiro C.J., et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 83 (1991) 997-1003
20. Burk R.D., Kelly P., Feldman J., Bromberg J., Vermund S.H., DeHovitz J.A., et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 23 (1996) 333-341
21. Kjaer S.K., Svare E.I., Worm A.M., Walboomers J.M., and Meijer C.J. van der Brule AJ. Human papillomavirus infection in Danish female sex workers. Decreasing prevalence with age despite continuously high sexual activity. Sex Transm Dis 27 (2000) 438-445
22. Persson G., Andersson K., and Krantz I. Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture. Acta Obstet Gynecol Scand 75 (1996) 287-290
23. Palefsky J.M. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 15 (2003) 382-388
24. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 37 (2001) S4-S66
25. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
26. Weir H.K., Thun M.J., Hankey B.F., Reis L.A., Howe H.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (2003) 1276-1299
27. Overview: Cervical cancer: How many women get cancer of the cervix? American Cancer Socety, Inc. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_women_get_cancer_of_the_cervix_8.asp?sitearea=. Accessed July 2, 2006.
28. Insinga R.P., Dasbach J., and Elbasha E.H. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 23 (2005) 1107-1122
29. Alam M., and Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol 137 (2001) 337-341
30. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (2003) 218-226
31. Kjaer S.K., Chackerian B., van der Brule A.J., Svare E.I., Paull G., Walbomers J.M., et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 10 (2001) 101-106
32. Syrjanen S., and Puranen M. Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med 11 (2000) 259-274
33. Manhart L.E., and Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29 (2002) 725-735
34. Franco E.L., Schlecht N.F., and Saslow D. The epidemiology of cervical cancer. Cancer J 9 (2003) 348-359
35. Pater M.M., Mittal R., and Pater A. Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses. Trends Microbiol 2 (1994) 229-234
36. Heim K., Christensen N.D., Hoepfl R., Wartusch B., Pinzger G., Zeimer A., et al. Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups. J Infect Dis 172 (1995) 395-402
37. Schiller J.T., and Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2 (2004) 343-347
38. Malejczyk J., Majewski S., and Jablonska S. Cellular immunity in cutaneous and genital HPV infections. Clin Dermatol 15 (1997) 261-274
39. Kjaer S.K., van der Brule A.J., Paull G., Svare E.I., Sherman M.E., Thompson B.L., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325 (2002) 572
40. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10 (2003) 108-115
41. Stanley M., Lowy D.R., and Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 24S3 (2006) S106-S113
42. Bhawan J., Dayal Y., and Bhan A.K. Langerhans cells in molluscum contagiosum, verruca vulgaris, plantar wart, and condyloma acuminatum. J Am Acad Dermatol 15 (1986) 645-649
43. Giannini S.L., Hubert P., Doyen J., Boniver J., and Delvenne P. Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer 97 (2002) 654-659
44. Hubert P., Caberg J.H., Gilles C., Bousarghin L., Franzen-Detrooz E., Boniver J., et al. E-cadherin-dependent adhesion of dendritic and Langerhans cells to keratinocytes is defective in cervical human papillomavirus-associated (pre)neoplastic lesions. J Pathol 206 (2005) 346-355
45. Jimenez-Flores R., Mendez-Cruz R., Ojeda-Ortiz J., Munoz-Molina R., Balderas Carillo O., de la Luz Diaz-Soberanes M., et al. High-risk human papillomavirus infection decreases the frequency of dendritic Langerhans' cells in the human female genital tract. Immunology 117 (2006) 220-228
46. Azar K.K., Tani M., Yasuda H., Sakai A., Inoue M., and Sasagawa T. Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum Pathol 35 (2004) 1376-1384
47. Fernandes A.P., Goncalves M.A., Duarte G., Cunha F.Q., Simões R.T., and Donadi E.A. HPV16, HPV18, and HIV infection may influence cervical cytokine intralesional levels. Virology 334 (2005) 294-298
48. Simões R.T., Goncalves M.A., Donadi E.A., Simões A.L., Bettini J.S., Duarte G., et al. Association of tumor necrosis factor a-2 and a-8 microsatellite alleles with human papillomavirus and squamous intraepithelial lesions among women in Brazil. J Clin Microbiol 43 (2005) 3932-3937
49. * 03 and cervical intra-epithelial neoplasia. Mol Med 1 (1995) 161-171
50. Odunsi K., Terry G., Ho L., Bell J., Cuzick J., and Ganesan T.S. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer 67 (1996) 595-602
51. Storey A., Thomas M., Kalita A., Hardwood C., Gardiol D., Mantovani F., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393 (1998) 229-234
52. Stanley M.A. Human papillomavirus and cervical carcinogenesis. Best Pract Res Clin Obstet Gynaecol 15 (2001) 663-676
53. Garcia-Closas R., Castellsague X., Bosch X., and Gonzalez C.A. The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. Int J Cancer 117 (2005) 629-637
54. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. [see comment]. Lancet Oncol 6 (2005) 271-278
55. Merck's New Cervical Cancer Vaccine, Gardasil®, Unanimously Recommended by CDC Advisory Panel for Vaccination of Girls and Women 11 to 26 Years. Available at: http://www.merck.com/newsroom/press_releases/product/2006_0629.html. Accessed July 4, 2006.
56. Merck's Cervical Cancer Vaccine, GARDASIL®, added to the CDC vaccines for children contract. Available at: http://www.merck.com/newsroom/press_releases/product/2006_1101.html. Accessed November 4, 2006.
57. European Commission Approves GARDASIL®, Merck's Cervical Cancer Vaccine. Available at: http://www.merck.com/newsroom/press_releases/product/2006_0922a.html. Accessed November 4, 2006.
58. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93 (2001) 284-292
59. Block S.L., Nolan T., Sattler C., Barr E., Glacoletti K.E., and Marchant C.D. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006) 2135-2145
60. Gardasil® Information for Healthcare Professionals. Available at: http://www.gardasil.com/hcp.html. Accessed July 15, 2006.
61. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
62. Coleman N., Birley H.D., Renton A.M., Hanna N.F., Ryait B.K., Byrne M., et al. Immunological events in regressing genital warts. Am J Clin Pathol 102 (1994) 768-774
63. Campo M.S. Vaccination against papillomavirus in cattle. Clin Dermatol 15 (1997) 275-283
64. Han R., Peng X., Reed C.A., Cladel N.M., Budgeon L.R., Pickel M.D., et al. Gene gun-mediated intracutaneous vaccination with papillomavirus E7 gene delays cancer development of papillomavirus-induced skin papillomas on rabbits. Cancer Detect Prev 26 (2002) 458-467
65. Vandepapeliere P., Barrasso R., Meijer C.J., Walboomers J.M., Wetterndorff M., Stanberry L.R., et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 192 (2005) 2099-2107
66. Santin A.D., Bellone S., Gokden M., Cannon M.J., and Parham G.P. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 346 (2002) 1752-1753
67. Mounsey A.L., Matthew L.G., and Slawson D.C. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician 72 (2005) 1075-1080
68. Gourishankar S., McDermid J.C., Jhangri G.S., and Preiksaitis J.K. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 4 (2004) 108-115
69. Schuchter L.M., Wingard J.R., Piantadosi S., Burns W.H., Santos G.W., and Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood 74 (1989) 1424-1427
70. Glesby M.J., Moore R.D., and Chaisson R.E. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 21 (1995) 370-375
71. Gilden D.H., Kleinschmidt-DeMasters B.K., LaGuardia J.J., Mahalingam R., and Cohrs R.J. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 342 (2000) 635-645
72. Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 10 (1996) 571-581
73. Mullooly J.P., Riedlinger K., Chun C., Weinmann S., and Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 133 (2005) 245-253
74. Wung P.K., Holbrook J.T., Hoffman G.S., Tibbs A.K., Specks U., Min Y.I., et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 118 (2005) 1416
75. Goldman G.S. Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology. Vaccine 23 (2005) 3349-3355
76. Yih W.K., Brooks D.R., Lett S.M., Jumaan A.O., Zhang Z., Clemens K.M., et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 5 (2005) 68
77. Volpi A. Varicella immunization and herpes zoster. Herpes 12 (2005) 59
78. Schuette M.C., and Hethcote H.W. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol 61 (1999) 1031-1064
79. Brisson M., Edmunds W.J., Gay N.J., and Miller E. Varicella vaccine and shingles. JAMA 287 (2002) 2211
80. Jumaan A.O., Yu O., Jackson L.A., Bohlke K., Galil K., and Seward J.K. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 191 (2005) 2002-2007
81. Croen K.D., and Straus S.E. Varicella-zoster virus latency. Annu Rev Microbiol 45 (1991) 265-282
82. Meier J.L., and Straus S.E. Comparative biology of latent varicella-zoster virus and herpes simplex virus infections. J Infect Dis 166 (1992) S13-S23
83. Morizane S., Suzuki D., Tsuji K., Oono T., and Iwatsuki K. The role of CD4 and CD8 cytotoxic T lymphocytes in the formation of viral vesicles. Br J Dermatol 153 (2005) 981-986
84. Levin M.J., and Hayward A.R. The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin North Am 10 (1996) 657-675
85. Tyring S.K. Natural history of varicella zoster virus. Semin Dermatol 11 (1992) 211-217
86. Hambleton S., and Gershon A.A. Preventing varicella-zoster disease. Clin Microbiol Rev 18 (2005) 70-80
87. Levin M.J., Smith J.G., Kaufhold R.M., Barber D., Hayward A.R., Chan C.Y., et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 188 (2003) 1336-1344
88. Levine M.J., Ellison M.C., Zerbe G.O., Barber D., Chan C., Stinson D., et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 18 (2000) 2915-2920
89. Smith J.G., Levin M., Vessey R., Chan I.S., Hayward A.R., Liu X., et al. Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization. J Med Virol 70 Suppl 1 (2003) S38-S41
90. Levin M.J., Barber D., Goldblatt E., Jones M., LaFleur, Chan C., et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 178 (1998) S109-S112
91. Hayward A.R., Buda K., Jones M., White C.J., and Levin M.J. Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunol 9 (1996) 241-245
92. Hayward A.R., Buda K., and Levin M.J. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunol 7 (1994) 31-36
93. Hata A., Asanuma H., Rinki M., Sharp M., Wong R.M., Blume K., et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347 (2002) 26-34
94. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
95. Zostavax®. Available at: http://www.zostavax.com/. Accessed July 15, 2006.
96. Edmunds W.J., Brisson M., and Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19 (2001) 3076-3090
97. Hornberger J., and Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 145 (2006) 317-325